Logo

RADX

Radiopharm Theranostics Limited

RADX

Radiopharm Theranostics Limited • NASDAQ
$4.58 ▼ -1.29% (-0.06)
Market Cap $5.90 M
52w High $50.82
52w Low $3.50
Dividend Yield 0%
P/E -1.33
Volume 2.49K
Outstanding Shares 1.29M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2024 $36.437M ▲ $92.452M ▲ $40.449M ▼ $53.202M ▲
Q4-2023 $18.575M ▲ $72.036M ▲ $44.683M ▲ $28.123M ▲
Q2-2023 $1.894M ▼ $63.293M ▼ $38.95M ▲ $24.234M ▼
Q4-2022 $11.699M ▼ $74.95M ▼ $29.37M ▲ $44.384M ▼
Q4-2021 $26.979M $83.381M $20.419M $62.963M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2024 $0 $-8.739M ▲ $2.592K ▼ $-2.14M ▼ $-9.994M ▼ $-8.739M ▲
Q1-2024 $0 $-13.477M ▼ $2.995M ▲ $38.749M ▲ $27.856M ▲ $-13.477M ▼
Q4-2023 $0 $-7.042M ▼ $0 $22.793M ▲ $15.637M ▲ $-7.042M ▼
Q3-2023 $0 $-4.2M ▼ $0 $5.179M ▲ $1.044M ▲ $-4.2M ▼
Q2-2023 $0 $-1.905M $0 $1.98M $60K $-1.905M

Five-Year Company Overview

Income Statement

Income Statement Income statement Radiopharm is still a pure research‑stage company: it has no product sales yet and all activity flows through research and corporate expenses. As a result, it reports recurring operating losses each year. Those losses have been relatively small in absolute size but have widened over time as the company has invested more in development and listing costs. The pattern is what you would expect from an early‑stage biotech: no revenue, steady spending on trials and infrastructure, and negative earnings per share driven by those costs rather than by any operational misstep in a commercial business.

Balance Sheet

Balance Sheet Balance sheet The balance sheet is light and simple. Assets are modest and largely made up of cash and related items, with no meaningful physical asset base and no financial debt. Equity provides essentially all of the funding, but has trended down as losses accumulate, which slowly erodes the capital base. The absence of borrowing reduces financial risk, but the small size of the balance sheet and limited cash cushion underline that Radiopharm is dependent on continued access to external capital to fund its clinical programs over time.

Cash Flow

Cash Flow Cash flow Cash flows reflect a company in build‑out mode. Operating cash flow is consistently negative as Radiopharm spends on research, clinical work, and public company costs without bringing in revenue to offset them. Free cash flow is also negative for the same reason, with only light capital spending so far. In practice, this means the company “burns cash” each year and must periodically refill its cash reserves through equity or partnership funding. The burn rate has been manageable relative to its size, but it is still the central financial risk to watch.

Competitive Edge

Competitive Edge Competitive position Radiopharm operates in a promising but highly competitive niche: radiopharmaceuticals for cancer. Its edge is a focused “theranostics” strategy, where the same biological target is used for both imaging and treatment, and a toolkit that spans nanobodies, antibodies, small molecules, and peptides. Targeting less crowded, first‑in‑class cancer pathways helps avoid direct head‑to‑head competition with larger players. Partnerships with MD Anderson and Lantheus add credibility, access to expertise, and potential commercial routes. On the other hand, Radiopharm is a small, pre‑revenue company competing in a field where large pharmaceutical companies with deep pockets are very active, which keeps execution and partnering strength critical to its competitive standing.

Innovation and R&D

Innovation and R&D Innovation & R&D Innovation is the core of Radiopharm’s value story. The company is advancing multiple radiopharmaceutical candidates that aim to both image and treat hard‑to‑manage cancers, using differentiated technologies like nanobodies and novel targets such as FASN, B7H3, and PD‑L1 with a radiotherapy twist. Several programs are already in early‑ to mid‑stage clinical trials, and one imaging agent has received regulatory fast‑track status, signaling recognition of unmet need. The pipeline is diversified across cancer types and mechanisms, which spreads scientific risk but also raises funding and execution demands. As with any clinical‑stage biotech, outcomes will be highly dependent on trial data, regulatory interactions, and the company’s ability to prioritize and progress the most promising programs.

Summary

Summary Radiopharm Theranostics is an early‑stage, oncology‑focused biotech with no current product revenue and a business model entirely built around developing first‑in‑class radiopharmaceuticals. Financially, it shows the standard profile of a pre‑commercial biotech: recurring operating losses, a small equity‑funded balance sheet, negative cash flow, and reliance on external capital. Strategically, its strength lies in a differentiated theranostic approach, a multi‑platform technology base, and notable partnerships that support both science and potential commercialization. The main opportunities are tied to successful clinical readouts and the broader growth of nuclear medicine, while the main risks stem from scientific uncertainty, trial and regulatory hurdles, funding needs, and competition from much larger industry players. Overall, this is a high‑risk, high‑uncertainty profile typical of clinical‑stage innovators, where value creation depends heavily on future clinical and partnership milestones rather than current financial performance.